前往 #ESMO26，带来膀胱癌的重要新进展
欧洲委员会批准 enfortumab vedotin + pembrolizumab 作为肌层浸润性膀胱癌的围手术期治疗，无论是否符合顺铂资格
一个将在马德里引发广泛讨论的新治疗格局 @OncoAlert
https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-perioperative-treatment-for-adults-with-resectable-muscle-invasive-bladder-cancer-mibc/
1048 浏览 · 13 赞 · 10 转发 · 0 回复
Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905
https://esmocongress.esmo.orgctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.orgHealth-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the phase 3 KEY
https://esmocongress.esmo.orgEnfortumab Vedotin (EV) With or Without Pembrolizumab (P) as First-Line (1L) Treatment for Cisplatin (cis)-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): Long-Term Follow-up Analysis from EV-103 Cohorts DE/A and K
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.orgEnfortumab Vedotin Plus Pembrolizumab (EV+P) For Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Updated Exploratory Analysis of EV-302 in Older Patients (pts) and Those With Comorbidities
https://esmocongress.esmo.org来源：Los Uromigos · x.com